Literature DB >> 31889626

Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis.

Diamantis I Tsilimigras1, Rittal Mehta1, Katiuscha Merath1, Fabio Bagante2, Anghela Z Paredes1, Ayesha Farooq1, Francesca Ratti3, Hugo P Marques4, Silvia Silva4, Olivier Soubrane5, Vincent Lam6, George A Poultsides7, Irinel Popescu8, Razvan Grigorie8, Sorin Alexandrescu8, Guillaume Martel9, Aklile Workneh9, Alfredo Guglielmi10, Tom Hugh11, Luca Aldrighetti3, Itaru Endo12, Timothy M Pawlik13.   

Abstract

BACKGROUND: Composite measures such as "Textbook Outcome" (TO) may be superior to individual quality metrics to assess surgical care and hospital performance. However, the incidence and factors associated with TO after resection of HCC remain poorly defined.
METHODS: Hospital variation in the rates of TO, factors associated with achieving a TO and the impact of TO on long-term survival following resection for HCC were examined using an international multi-institutional database.
RESULTS: Among 605 patients who underwent curative-intent resection of HCC, the unadjusted incidence of TO ranged from 50.9% to 77.7%. While achievement of each individual quality metric was relatively high (range, 74.5-98.0%), an overall TO was achieved among only 62.3% (n = 377) of patients. At the hospital level, TO ranged from 54.3% to 72.9%. Patients with BCLC-0 HCC (referent BCLC-B/C; OR: 4.17, 95%CI: 1.62-10.7) and ALBI grade 1 (referent ALBI grade 2/3; OR: 1.49, 95%CI: 1.06-2.11) had higher odds of achieving a TO. On multivariable analysis, TO was associated with improved overall survival (HR: 0.60, 95% CI: 0.42-0.85).
CONCLUSION: Roughly 6 in 10 patients achieved a TO following resection for HCC. When achieved, TO was associated with better long-term outcomes. TO is a simple composite measure of both short- and long-term outcomes among patients undergoing resection for HCC.
Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 31889626     DOI: 10.1016/j.hpb.2019.12.005

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  6 in total

1.  Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer.

Authors:  Sujay Kulshrestha; Wickii T Vigneswaran; Timothy M Pawlik; Marshall S Baker; Fred A Luchette; Wissam Raad; Zaid M Abdelsattar; Richard K Freeman; Tyler Grenda; James Lubawski
Journal:  Semin Thorac Cardiovasc Surg       Date:  2021-08-16

2.  Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.

Authors:  Daniel Azoulay; Emilio Ramos; Margarida Casellas-Robert; Chady Salloum; Laura Lladó; Roy Nadler; Juli Busquets; Celia Caula-Freixa; Kristel Mils; Santiago Lopez-Ben; Joan Figueras; Chetana Lim
Journal:  JHEP Rep       Date:  2020-10-08

3.  Influence of surgical approach and quality of resection on the probability of cure for early-stage HCC occurring in cirrhosis.

Authors:  Christian Hobeika; Jean Charles Nault; Louise Barbier; Lilian Schwarz; Chetana Lim; Alexis Laurent; Suzanne Gay; Ephrem Salamé; Olivier Scatton; Olivier Soubrane; François Cauchy
Journal:  JHEP Rep       Date:  2020-07-30

4.  Textbook outcome among voluntary donors undergoing major living donor hepatectomy.

Authors:  Abu Bakar Hafeez Bhatti; Wajih Naqvi; Nazish Ali; Nusrat Yar Khan; Haseeb Haider Zia; Belqees Yawar Faiz; Abid Ilyas; Atif Rana; Nasir Ayub Khan
Journal:  Langenbecks Arch Surg       Date:  2022-06-07       Impact factor: 2.895

5.  Textbook outcomes in hepatobiliary and pancreatic surgery.

Authors:  Diamantis I Tsilimigras; Timothy Michael Pawlik; Dimitrios Moris
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

6.  Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: Pancreaticoduodenectomy.

Authors:  Ahmad Hamad; Timothy M Pawlik; Aslam Ejaz
Journal:  Ann Surg Oncol       Date:  2021-02-23       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.